1. Medtech Insight
  2. >>Business
  3. >>Strategy

Covidien Sells One Peripheral Device While Touting Data On Another

Covidien announced it is selling its Stellarex drug-coated angioplasty balloon platform to Spectranetics for $30 million ahead of its merger with Medtronic, which makes the IN.PACT Admiral drug-coated balloon. But the company still plans to bring a significant peripheral vascular device portfolio along with it when it joins Medtronic.

Medtronic Minimally Invasive Therapies remains optimistic about its peripheral vascular device business even as it sells its Stellarex drug-coated peripheral angioplasty balloon to Spectranetics Corp. in anticipation of its merger with Medtronic PLC

“I think under the new company, this is going to be a powerhouse in peripheral vascular,” Covidien CEO José Almeida...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

AngioSafe Eyes Coronary And Below-The-Knee Indications Ahead Of US Launch Of Santreva-ATK

 
• By Shubham Singh

The Santreva-ATK system integrates axial plaque traversal, lateral plaque compression and channel formation into a single mechanism, simplifying procedures that previously required sequential steps. The system directs the physician’s energy toward the plaque while protecting the vessel wall.

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 
• By Amanda Maxwell

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By Marion Webb

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Dexcom Pushes Forward With R&D Growth, New Devices Amid Scrutiny And Shake-Up

 
• By Marion Webb

Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.

More from Business

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By Elizabeth Orr

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

Confido CEO Predicts AI For Repetitive Tasks Will Become As Essential To Clinics As Basic Hygiene

 
• By Marion Webb

Confido Health has raised $10m in Series A funding to expand its AI voice agent from patient scheduling into referrals, prescriptions and billing, bringing the total collected to $13m. CEO Chetan Reddy predicts in the next decade, AI use for admin tasks in healthcare will become mainstream.

Dexcom Pushes Forward With R&D Growth, New Devices Amid Scrutiny And Shake-Up

 
• By Marion Webb

Dexcom has endured recalls, layoffs and leadership change, but interim CEO Jake Leach said the company remains committed to innovating next-gen devices.